SKAN Group AG

Investor Presentation • Sep 17, 2025

SKAN Group Investor Presentation

September 2025

Disclaimer

THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

This presentation ( the "Presentation"), contains information regarding SKAN Group AG (the "Company") and each of its subsidiaries and affiliates (the "Group"). The information and opinions contained in this Presentation do not purport to be comprehensive and are provided as at the date of this Presentation or as of the date specified herein. Certain financial information (including percentages) in this Presentation may have been rounded according to commercial standards. As a result, the aggregate amounts may not correspond in all cases to the aggregated amounts of the underlying (unrounded) figures appearing elsewhere in this Presentation.

The financial information presented herein has been prepared in accordance with Swiss GAAP FER. Certain financial data included in this Presentation consists of non-Swiss GAAP FER financial measures. These non-Swiss GAAP FER financial measures may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other financial measures determined in accordance with Swiss GAAP FER. In addition, certain financial information contained herein has not been audited, confirmed or otherwise covered by a report by independent accountants and, as such, actual data could vary, possibly significantly, from the data set forth herein. None of the Company, the Group, and any other person is under any obligation to update or keep current the information contained in this Presentation or to correct any inaccuracies which may become apparent, and any opinions expressed herein are subject to change without notice.

Statements made in this Presentation may include forward-looking statements. These statements may be identified by the fact that they use words such as "anticipate", "estimate", "should", "expect", "guidance", "project", "intend", "plan", "believe", "will", "could" and/or other words and terms of similar meaning in connection with, among other things, any discussion of results of operations, financial condition, liquidity, prospects, growth, strategies or developments in the industry in which we operate. Such statements are based on management's current intentions, expectations or beliefs and involve inherent risks, assumptions and uncertainties, including factors that could delay, divert or change any of them. Forward-looking statements contained in this Presentation regarding trends or current activities should not be taken as a representation that such trends or activities will continue in the future. Actual outcomes, results and other future events may differ materially from those expressed or implied by the statements contained herein. Such differences may adversely affect the outcome and financial effects of the plans and events described herein and may result from, among other things, changes in economic, business, competitive, technological, strategic or regulatory factors and other factors affecting the business and operations of the company. Neither the Company nor any of their subsidiaries or affiliates are under any obligation, and each such entity expressly disclaims any such obligation, to update, revise or amend any forward-looking statements, whether as a result of new information, future events or otherwise.

Further, this Presentation may include market share and industry data obtained by the Company from industry publications and market surveys. The Company may not have access to the facts and assumptions underlying the numerical data, market data and other information extracted from public sources and neither the Company, the Group, nor any of their respective directors, officers , employees, shareholders, affiliates, agents and advisers are able to verify such information, and assume no responsibility for the correctness of any such information.

This Presentation does not constitute or form part of, and should not be construed as, an offer or invitation or inducement to subscribe for or otherwise acquire, any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Group, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This Presentation does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). Neither the Company nor any other member of the Group has registered or intends to register any securities under the Securities Act or the securities laws of any state or other jurisdiction of the United States.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF THE COMPANY OR THE GROUP.

Global market leader for aseptic process solutions

• Global market leader in high-end isolator solutions for aseptic production processes across (bio-) pharma
• Pioneer in isolator technology with 50+ years of experience
• Trusted, long-term partner to almost all major (bio-)pharma companies
• Diversified customer base with more than 1,000 total active customers
• Global footprint across Europe, America and Asia

Who is SKAN ? SKAN aseptic process offering

Equipment & Solutions (75%)

• Customized and standard isolator solutions
• Automated aseptic filling stations, e.g. for cell & gene therapy
• Process solution from design & engineering to process qualification

SKAN key figures 2024

Services & Consumables (25%)

• Lifecycle management
• Spare parts
• Consumables: closed vials, transfer connectors, Betabags, etc.
• Digital integration with MES(2) and into ERP systems

⁽¹⁾ Management estimation of the market share within the premium high-value market (2) Manufacturing Execution System September 2025 3

Key challenge for (bio-)pharmaceutical products

Key challenge	Products	In particular true for
Medical safety	Injectables	High-value biopharma drugs
Medication safety is key and (cross-) contamination unacceptable Key contamination sources: Air particles Input: Raw materials, containers, closures Personnel	Cancer drugs: Antibody Drug Conjugates (ADC), Cytotoxics Infection risk Cell & gene therapy: Advanced as application Therapy Medicinal Products (ATMPs)) bypasses natural Hormones: GLP-1, Insulin defenses of the Medical drugs: Thrombosis, EPO, human body blood plasma products, botox, etc. Vaccines: Flu, etc.	Risk of significant economic losses if high-value biopharma drugs get contaminated Risk of cross-contamination increases with small batch size of fast-growing personalized medicine

Isolators – Mission critical for (bio-)pharmaceutical processes

Solution: Medication sterility

Technological edge & innovation

• Technology leadership & foresight allows SKAN to be the market defining player
  • Continuous active contribution to new guidelines & regulations through industry standards setting organizations (ISPE, PDA, ISO)
• Pure-play business model enables an undiluted focus of resources to drive technology and innovation
• Approx. 1500 employees, of which more than 50% have an academic background such as scientists and engineers ensure seamless innovation and production

minutes

Structural growth drivers support SKAN's long-term expansion

Demographic trend and lifestyle promote chronical diseases Development process of new biotech drugs speeding up Double digit growth of underlying biologics market Complex molecules are difficult and expensive to produce Containment during production is key for sterility and protection Isolator technology provides highest safety and quality advantages Sensitive in production Cannot be terminally sterilized Are typically of high value Dosing is key Injectable dosage form Injectable drugs need to be sterile when administered Some molecules are harmful if exposed to manufacturing and health care personnel Highly regulated (GMP) Aseptic environment Adaptive to sensitive drugs Operator and cross contamination protection Lower running costs (energy, quality)

The demand for injectable drugs will continue to grow structurally

Growth drivers for the biopharmaceutical market

Demand for isolators will grow with the industry and continue to replace older technologies

Growth drivers for isolators in fill finish

SKAN's leadership position is underpinned by high entry barriers and compelling value proposition

Entry barriers SKAN's value proposition		Key purchasing criteria
Technological	Mastery of difficult to replicate know-how on	Product quality / reliability
edge	highest-performance isolators	Brand reputation
	nce	Validation process support
Stringent regulatory	Process warranty regarding all regulatory orta (e.g. FDA, EMA, Swissmedic) required p	Aftersales service / proximity
environment	m qualifications & timeline g relative i	Relationship / track record
		Delivery time / reliability
Mission criticality of aseptic processes	Decreasin Swiss brand, engineering & reputation provide trust in isolator safety	Customisation capabilities
		Innovation and R&D capabilities
Lock-in effect	Large installed base of isolators and leading global services incl. tech transfer &	Breadth of product offering
	consumables across product lifecycle	Price / TCO

SKAN is focused on high value isolators, in particular the premium high-value segment of the market

Trusted, long-term partner for global (bio-)pharma customers

Selected (bio-)pharma customers… Key statistics

High level of recurring customers

Number of clients & order intake share by type of client(1)

Loyal customers

Share of top 100 customers over 2012-2023 contributing to 70.6% of total order intake over last 11 years(1)

• New clients (2018–2023)
• Opportunistic clients

Recurring clients (Continuous new order intake) New clients (First order intake)

(1) Analysis based on customers of SKAN AG (SKAN AG includes almost all of SKAN's projects while Service & Consumables may be ordered on the local subsidiary level). SKAN Group AG Investor Presentation 11

Comprehensive portfolio for aseptic manufacturing processes

	Cleanroom Business Pure contrib. Solutions	Customized and modular isolators Process Solutions	Business contrib.	Integrated processes Integrated Process Solutions	Business contrib.
s n o uti ol S") S & & nt E (" e m p ui q E 75% of sales	Pure Solutions Trading Trading of Laboratory/ cleanroom equipment, mostly in Switzerland Horizontal/verti cal workbenches Fume cupboards Particle counters	Customized Solutions ("CusSol") Customer-specific isolator solutions for aseptic manufacturing and filling Process warranty incl. complete GMP compliance	System Solutions ("SysSol") Modular isolators equipped flexibly with process tools Close collaboration with process tool partners	Aseptic Technologies (AT) Proprietary, automated closed-vial filling equipment for small/medium-batch cell & gene therapy integrated within isolator	Process Automation Global process solution providing automated (robotic) process handling fully integrated within the isolator
s e bl C") a m & u S s (" n o C 25% of sales	Consumables Personal protective equipment Biosanitizer Services Qualification	Consumables Betabags Electron Beam (bulbs) Spares (gloves, filters, etc.)	Services Life cycle support GMP requalification Performance, material and CFD studies and cleaning validation Digital integration with MES(1) and into ERP systems Retrofit (Upgrades)	Consumables Closed vials Connectors Filling kits Services Rent a machine Life cycle support	Consumables Refer to process consumables Services Refer to process services Digital integration with MES(1) and into ERP systems

Services &

One-stop-shop across the entire lifecycle of SKAN's missioncritical aseptic process solutions

(1) Value creation is an approximation for the value-add provided in each step in a typical project of an isolator process solution for a client and is based on SKAN's Percentage-of-Completion method for invoicing clients throughout the project. The Percentage -of-Completion for milestones vary from project to project and should be considered as indicative approximation only. SKAN Group AG Investor Presentation 13

Stronger customer proximity through accelerated decentralization and expanded offering

Allschwil CH

Headquarters / production sites Engineering, sales, service, assembly, R&D, laboratories

Stein CH

Production site Prototype construction, steelwork, ebeam competence

São Paulo BR Sales & services office Sales and life cycle support South America

Raleigh US Sales & services office Sales and life cycle support US

Görlitz DE

Production site Focus: steelwork, production, assembly, qualification

Okinawa JP Production site Sales, assembly, and life cycle support Far East

ABC Transfer® Chambray-lès-Tours FR

Transfer-Systems & Betabag Designing, manufacturing and distributing sterile transfer solutions for pharmaceutical applications

Aseptic Technologies Gembloux & Ans BE Aseptic manufacturing process Aseptic Filling equipment & Closed Vial® Technology

Metronik Ljubljana SI & Zagreb HR

Software solutions Manufacturing digitalization of lifesciences industry (Manufacturing Execution System (MES))

Experienced, entrepreneurial management and highly qualified workforce loyal to the firm

Dedicated workforce

Headcount Headcount still with SKAN today

September 2025

Board of Directors

Beat Lüthi Chairman

Cornelia Gehrig Gregor Plattner Oliver Baumann Patrick Schär Thomas Huber

SKAN

Experienced management team

Vice Chairwoman

(1) All figures as of December of respective year and exclusive of temporary workers. SKAN Group AG Investor Presentation 15

Sustainability highlights

Isolators enable the filling of life-saving medication: cancer drugs, cell & gene drugs, hormones, vaccines, …

One out of three isolator-filled vaccines in regulated markets (Europe, North America, Japan, Singapore, South Korea) is filled in a SKAN isolator(1)

Certified as "great place to work"

Certified equal pay policy(2)

87,799 hours of training in 2024.

Diverse workforce with 50 nationalities & inclusive hiring(3)

Group-wide decentralization and roll-out of SKAN Academy to reduce (air) travel

20-30% more energy efficient isolator technology compared to cleanrooms(1)

453,936 kWh (+93% vs. PY) electricity produced with solar panels on SKAN buildings(4)

~15% of the vehicle fleet use solar power produced in-house

(1) Management estimates

• (2) Currently in Switzerland certified for equal payment for men & women
• (3) 3 social positions, 1 IV reintegration, disabled persons
• (4) Contains production in Allschwil, Stein, Raleigh and Görlitz

Excellent track-record with consistent above-market growth and increasing profitability

Net sales & order intake (CHFm)

Order intake

Rounding differences may occur (1) Defined as reported EBIT / (Total Assets – Short-term Liabilities) September 2025 SKAN Group AG Investor Presentation 17

SKAN Group's growth strategy

Continue growth track-record Increase recurring revenue base Expand profitability

Fortify market leadership

• Investment in production capacity expansion and scale-up
• Continuous innovation to meet customer's demand and to maintain technical leadership
• Continuous active contribution to new guidelines & regulations
• Grow service revenues with everincreasing installed base of isolators

technology

Expand addressable market towards integrated process

▪ Scale-up of Aseptic Technologies ▪ Intensified joint developments with established fill-finish partners

▪ In-house development of Integrated Process Solutions combining automated robotics with isolator

• Increase exposure to aftermarket services & consumables revenues
• Expand offering to include software and digital integration services
• Increasing, global product lifecycle support with expanding installed base of isolators
• Further development of innovative consumables (e.g. closed vials, transfer systems, filling kits, betabags)
• Additional service offerings of "pre-approved" services to help customers shorten time-to-market

• Accelerate digital transformation
• Offer proprietary Manufacturing execution system (MES)
• Industry 4.0
  • "One button release" paperless GMP compliant documentation
  • Artificial Intelligence for preventive maintenance
• Increased augmented reality service virtual reality design support

Integrated Process Solutions enable greater flexibility, robustness and efficiency

SKAN

Robotics and data management for integrated aseptic manufacturing

Flexible solutions for a range of aseptic process handling applications

Automated robotics offer a high level of processes robustness, i.e. more reproducible and accurate

Robotic systems offer significant time efficiency advantages vs. traditional methods translating into much faster production times

Reducing the amount of human contact involved in a production process, thereby minimizing the risk of human contamination

New drugs increase closed vial demand

Eight AT filled drugs on the market

Customer	Product area	Phase
	DELYTACT®: Oncolytic virotherapy for brain cancer
	ARTI-CELL® FORTE: Cartilage repair for veterinary applications
	CARVYKTI : Lentivirus used for the production of a drug against multiple myeloma
	EBVALLO : Monotherapy for the treatment of Epstein Barr virus
	VYJUVEK : Treatment of wounds in patients with dystrophic epidermolysis bullosa in collagen type VII alpha 1 chain gene
	CASGEVY : Therapy for the treatment of sickle cell disease and transfusion-dependent Beta Thalassemia
	BEQVEZ / DURVEQTIX®: Therapy to treat Hemophilia B
	RYONCIL®: The first FDA-approved Mesenchymal Stomal Cell (MSC) therapy
September 2025	SKAN Group AG Investor Presentation	Explanation of abbreviations:

Explanation of abbreviations: FDA: Food and Drug Administration

EMA: European Medicines Agency

MHRA: Medicines and Healthcare products Regulatory Agency

• Aseptic Technologies (AT) provides automated, robotassisted process solutions for closed vials for applications in cell and gene therapy.
• Sales of AT-Closed Vial® and associated disposable products such as filling kits are a driver for the Services & Consumables business.
• Today, 8 in AT vials filled drugs are on the market and received 17 approvals by 6 major health authorities, including FDA, MHRA and EMA.
• The development pipeline of drugs in AT-Closed Vial® contains several hundred active ingredients.
• The commercialization of new drugs will further increase the consumption of AT-Closed Vial®, disposable products and AT production equipment.

2

3

Accelerated go-to-market for our customers with Pre-Approved services – enabling faster access for patients

Pre-Approved services launch planned in H2/2026

SKAN

• With Pre-Approved Services, SKAN will offer customers the possibility to carry out their stability tests on our systems.
• This will allow our customers to shorten the time-to-market for a new drug significantly.
• Significant investments were made by SKAN to develop preapproved services.
• SKAN seeks regulatory approval in Q1 2026 and intends commercial production in H2 2026.

Key data

• Equipment:
  • At start: filling equipment with potential to expand
  • At full capacity: a wide range of products can be handled

Commercial use:

H2/2026E: Planned start of commercial use with successive increase in capacity utilization over several years until full capacity is reached

s e n o st e Mil	Concept approved	Start interior fitting	Start realization of infrastructure and cleanroom	All equipment brought in, start of installation	Validation completed, start approval process	Regulatory approval	Start of commercial use
	Q1/2023	Q3/2023	Q1/2024	Q3/2024	Q3/2025E	Q1/2026E	H2/2026E increase capacity utilization

Metronik – providing the digital backbone of modern pharma production environments

Metronik is a leading provider of digitalization and automation systems and solutions.

Increase exposure to aftermarket services & consumables revenues

4

Accelerate digital transformation

3

• Metronik's modular, web-based software serves as digital backbone of modern pharma production and meets the highest standards in the strictly regulated GMP setting.
• Strong focus on the regulated life sciences sector with blue chip clients such as Novartis, Sandoz, Stada.
• The combination of SKAN's aseptic expertise and Metronik's digital process integration creates added value for customers.
• SKAN and Metronik share an entrepreneurial culture with uncompromising customer focus.
• Founded in 1990 and headquartered in Ljubljana, Slovenia, Metronik employs over 160 highly qualified people and serves over 100 customers.

ABC Transfer – specialized in transfer systems for the aseptic filling of pharmaceuticals

02

Alpha stainless steel door

• Assembly on isolators
• Receive beta containers or betabags

Betacleancontainer

• Connects to Alpha doors.
• Ensures sterility and containment for the passage of tools.

03

Betacleanbag

• Connects to doors
• Ensures the passage of components or active ingredients.
• ABC Transfer is a leading innovator in patented secure rapid transfer systems, enhancing efficiency in pharmaceutical production.
• Offers several types of registered products:

3

• 1. sterile transfer ports
• 1. sterile containers and
• 1. sterile transfer bags
• The products are compatible with existing market solutions and meeting Annex 1 requirements.
• Wide network of blue chip clients such as Novo Nordisk, Lilly, Merck.
• Entrepreneurial culture with uncompromising customer focus.
• Founded in 2019 and headquartered in Tours, France, ABC Transfer employs 11 highly qualified people and serves over 75 customers.

SKAN

Increase exposure to aftermarket services & consumables revenues

Several drivers for margin expansion

Comments

• Strategic goal: >50% of EBITDA from scalable recurring revenues (Services & Consumables)
• Key margin drivers:
  • Accelerated growth of the high-margin consumables business
  • Cost leverage in other operating expenses
  • Increased standardization in assemblies and processes to boost core business efficiency
• Scalable, high-margin revenues from strategic initiatives Integrated Process Solutions and Pre-Approved services
• Recurring after-sales revenues driven by a growing installed base …by segments

(1) directly expensed in the P&L (2) Illustrative graph

SKAN continues to invest significantly in its future growth

Further capital allocation

Opportunistic M&A strategy based on the following

High-barrier niche markets with growth potential

• Main investments:
  • Pre-Approved services incl. expansion within existing facilities
  • Central Hub in Germany to streamline material flows across the supply chain
  • Expand production capacity for closed vial technology
  • Build-up production capacity in the USA
• Potential further expansion of Pre-Approved services in other regions with a positive impact on financials beyond mid-term.
• With maintenance capex at approx. 3% of net sales, SKAN demonstrates a low level of capital intensity, highlighting the efficiency and scalability of its business model.
• We are confidently funding our strategy and organic growth plans through consistently strong self-generated cash flows.

Century of biology: Shift toward injectable biotech drugs continues and drives need for aseptic process solutions

Confident market and business outlook

Market development

• SKAN continues to operate in a structurally growing market. Main drivers are:
  • The underlying growth of the global pharmaceutical and biotech market;
  • The reinforcing trend towards injectable drugs (three quarters of drugs in development are designed for injectable dosage form);
  • The shift from traditional cleanrooms to the safer and more sustainable isolator technology;
  • The reshoring of pharmaceutical production.
• As a consequence, demand for process solutions for the aseptic filling of drugs and for the associated services and consumables will continue.

Business development

• Even though the cyclical nature of the first half of the year, which is typical for the business, was more pronounced than in previous years, we are confident that in the second half of the year the temporary gaps in net sales and EBITDA caused by project postponements will be closed.
• Optimism is fuelled by the strong order intake, the high order backlog and the full pipeline of requests for quotations.
• In addition, pre-production of standard isolators can be sold in the second half of the year.
• Together with Metronik, SKAN can now offer customers a comprehensive solution along the entire pharmaceutical value chain – from isolator technology and automation to fully digitalized and integrated manufacturing processes.

Financial targets and guidance

SKAN

Note: Rounding differences may occur.

(1) 2025 targets assume no further deterioration (direct or indirect) of economic general conditions and other unpredictable deve lopment of the geopolitical situation. (2) E&S refers to Equipment & Solutions. S&C refers to Services & Consumables

SKAN's investment highlights

• Market leader globally for high-end aseptic process solutions 1 2 3 4
• Technology & innovation leadership
• Strategically positioned in a highly dynamic & rapidly growing niche market
• Significant barriers to entry

- Trusted, long-term partner to a large, diversified customer base 5 6 8

• Experienced & entrepreneurial management with proven track record
• Excellent financial profile with demonstrated abovemarket growth 7

Clear strategy with multiple avenues for growth and margin improvement